A novel and effective treatment may be IL-33 therapy in combination with NF-kB inhibitors.CD8+ CTLs, an HLA class I co-stimulatory molecule, are a major effector cell for eliminating tumor cells (90). This evidence concerns the gene NFKB1 and neoplasm.